Molecular test allows for continuous, noninvasive monitoring and
CHICAGO--(BUSINESS WIRE)--Jun. 2, 2018--
Inc. (NASDAQ: NH), a leading next-generation, evidence-based,
personalized healthcare company, unveiled Liquid GPS™ a powerful
next-generation tool for blood-based tumor profiling and quantitative
NantHealth chose the American Society of Clinical Oncology (ASCO) 2018
Annual Meeting to showcase the potential of Liquid GPS™ — a blood-based
molecular test that provides oncologists with a powerful tool to
continuously monitor and profile tumors, an approach that is less
invasive than a traditional biopsy.
Liquid GPS™ expands upon NantHealth’s molecular analysis portfolio of
products — which includes the tissue-based GPS Cancer ™ solution. Liquid
GPS offers sophisticated analysis tools — looking beyond cfDNA to cfRNA.
This technology allows more comprehensive profiling and trending of
biomarkers that can’t be assessed by cfDNA alone. As a result, Liquid
GPS™ offers a richer portrait of a patient’s condition and offers more
therapeutic targets, such as chemotherapy and immunotherapy, than a
typical liquid biopsy.
“We believe the development of Liquid GPS is important to our broader
vision for fighting cancer from a biological, rather than an anatomical
perspective,” said Dr. Patrick Soon-Shiong, CEO of NantHealth “This test
is a non-invasive way to achieve molecular insights that could help
shape treatment and provide the oncologist and patients real-time
information on the status of the cancer. This work builds on what
NantHealth has already done with GPS Cancer as we focus on successfully
analyzing and treating cancer at the molecular level.”
More information about the significance and potential applications of
Liquid GPS™ please visit the NANT booth at #7147
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a
next-generation, evidence-base, personalized healthcare company enabling
improved patient outcomes and more effective treatment decisions for
critical illnesses. NantHealth’s focused portfolio exemplifies its
unique systems-based approach to personalized healthcare and integrates
novel analysis with large-scale, biometric and phenotypic data to track
patient outcomes and deliver precision medicine. For more information
please visit www.nanthealth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180602005038/en/
Source: NantHealth, Inc.
NANT MEDIA CONTACT
Jen Hodson, 562-397-3639